Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026051 · ClinicalTrials.gov registry record · Phase 2
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01026051: Clinical Trial Phase 2 study, sponsored by Mannkind Corporation.
NCT01026051 is a Phase 2 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026051, a Phase 2 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
Interventions
- BIOLOGICAL MKC1106-MT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Why NCT01026051 stopped before completion
NCT01026051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which MKC1106-MT is the first listed.
NCT01026051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01026051 about?
NCT01026051 is a clinical study titled "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma". The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
What is the current status of trial NCT01026051?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01026051?
The interventions under investigation include: MKC1106-MT (BIOLOGICAL).
Who is sponsoring clinical trial NCT01026051?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01026051's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia